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In Response:
We thank Jiang et al for their interest in our article on the comparison of cardiac 
myosin-binding protein C (cMyC) with high-sensitivity cardiac troponin (hs-cTn) 
for the diagnosis of acute myocardial infarction.1 Despite being invented >100 
years ago, we believe that the ECG is the most dynamic biomarker of myocardial 
ischemia because diagnostic ST-elevation occurs within 30 seconds of an epicardial 
coronary occlusion.2 Because this is close to the human circulation time, no circu-
lating biomarker can beat it. However, in the absence of diagnostic ECG changes, 
other approaches must be pursued.
The APACE study (Advantageous Predictors of Acute Coronary Syndrome Evalu-
ation) is designed to identify such approaches by enrolling all-comers presenting to 
the emergency department with chest pain regardless of initial electrocardiograph-
ic findings. However, most clinical pathways in Europe use prehospital ECG to 
select patients with ST-segment–elevation myocardial infarction (STEMI) for direct 
transfer to the nearest unit offering primary percutaneous coronary intervention.3 
This bypasses conventional emergency departments; thus, the patients “excluded” 
from our analysis because of STEMI are often “walk-ins” or, as Jiang et al point 
out, might have had a “nearly normal ECG” at first evaluation in the ambulance.
As requested, we have performed an analysis including patients with STEMI 
(previously excluded1), focusing on early presenters (≤3 hours since chest pain on-
set). We assessed biomarkers comparing median (interquartile range [IQR]) and 
discrimination power quantified by the area under the receiver-operating char-
acteristics curve using the DeLong et al4 findings for comparison. The area under 
the receiver-operating characteristics curve for STEMI was derived with a binary 
outcome (eg, STEMI true/false, non-STEMI excluded).
We had 659 complete data sets for cMyC, hs-cTnT, and hs-cTnI at presenta-
tion; 31 patients had a gold-standard diagnosis of STEMI, and 95 had non-STEMI. 
Median cMyC concentrations were 198 ng/L (IQR, 69–598 ng/L) for STEMI, 121 
ng/L (IQR, 44–623 ng/L) for non-STEMI, and 11 ng/L (IQR, 7–22 ng/L) for patients 
without acute myocardial infarction (P<0.001) compared with median hs-cTnT 
concentrations of 29 ng/L (IQR, 16–80 ng/L), 38 ng/L (IQR, 16–91 ng/L), and 7 ng/L 
(IQR, 4–12 ng/L), respectively (P<0.001) and median hs-cTnI concentrations of 44 
ng/L (IQR, 19–124 ng/L), 34 ng/L (IQR, 12–137 ng/L), and 3 ng/L (IQR, 2–6 ng/L), 
respectively (P<0.001).
Similar to the findings in the original article, in an assessment of the accuracy for the 
diagnosis of all acute myocardial infarction regardless of ECG findings, the area under 
the receiver-operating characteristics curve was higher for cMyC than hs-cTnT, 0.912 
(95% confidence interval [CI], 0.884–0.940) versus 0.888 (95% CI, 0.856–0.917; 
P=0.038), and comparable to hs-cTnI, 0.914 (95% CI, 0.889–0.939; P=0.850). For 
the discrimination between STEMI and non–acute myocardial infarction, the area un-
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der the receiver-operating characteristics curve was 0.912 
(95% CI, 0.840–0.983) for cMyC versus 0.889 (95% CI, 
0.836–0.942, P=0.499) for hs-cTnT and 0.930 for hs-cTnI 
(95% CI, 0.894–0.966; P=0.555).
The advantage of cMyC over hs-cTnT but not hs-
cTnI in early presenters seems to extend to patients 
with STEMI. However, a sample size of 31 patients is 
likely too small to make assumptions about the utility in 
patients with ST-segment changes. This does not pro-
vide a conclusive answer as to the value of cMyC in 
the assessment of patients with nearly normal ECGs, 
in patients whose ECG cannot be interpreted (eg, in 
the context of bundle-branch block morphology), or in 
patients who present even earlier. Clearly, these are as-
pects that require further research and a larger number 
of observations.
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